Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Cancer Research

• Publication date

  1993-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 7689420
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5‐fluorouracil‐induced stomatitis

  1990cited by this paper
• Treatment of colorectal cancer and other malignancies with continuous infusion of 5-fluorouracil.

  1989cited by this paper
• Low‐dose continuous infusion 5‐fluorouracil. Evaluation in advanced breast carcinoma

  1989cited by this paper
• A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.

  1989cited by this paper
• Allopurinol mouthwash for prevention of fluorouracil-induced stomatitis.

  1989cited by this paper
• Effects of the Plasma Concentration of 5‐Fluorouracil and the Duration of Continuous Venous Infusion of 5‐Fluorouracil with an Inhibitor of 5‐Fluorouracil Degradation on Yoshida Sarcomas in Rats

  1989cited by this paper
• Continuous 5‐Fluorouracil Infusion in Advanced Gastric Carcinoma

  1988cited by this paper
• Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts.

  1987cited by this paper
• Continuous 5-fluorouracil infusion in refractory carcinoma of the breast

  1987cited by this paper
• Phase II trial of high-dose continuous infusion 5-fluorouracil with allopurinol modulation in colon cancer.

  1986cited by this paper
• Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas.

  1985cited by this paper
• Allopurinol mouthwashes and 5-fluorouracil induced oral toxicity.

  1985cited by this paper
• Long‐term ambulatory treatment of metastatic colorectal adenocarcinoma by continuous intravenous infusion of 5‐fluorouracil

  1985cited by this paper
• A controlled trial of the effect of 4-hydroxypyrazolopyrimidine (allopurinol) on the toxicity of a single bolus dose of 5-fluorouracil.

  1985cited by this paper
• Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas.

  1985cited by this paper
• Allopurinol mouthwashes and 5-fluorouracil induced oral toxicity.

  1985cited by this paper
• 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity.

  1984cited by this paper
• Structure-activity relationship of pyrimidine base analogs as ligands of orotate phosphoribosyltransferase.

  1984cited by this paper
• Lack of inhibition by oxipurinol of 5-FU toxicity against human tumor cell lines.

  1983cited by this paper
• 5-FU and allopurinol: toxicity modulation and phase II results in colon cancer.

  1982cited by this paper
• Modulation of 5‐fluorouracil toxicity by allopurinol in man

  1981cited by this paper
• Allopurinol modification of the toxicity and antitumor activity of 5-fluorouracil.

  1980cited by this paper
• Allopurinol modulation of high-dose fluorouracil toxicity.

  1979cited by this paper
• Effect of uracil on metabolism of 5-fluorouracil in vitro.

  1979cited by this paper
• Selective antagonism of 5-fluorouracil cytotoxicity by 4-hydroxypyrazolopyrimidine (allopurinol) in vitro.

  1979cited by this paper
• Allopurinol modulation of high-dose fluorouracil toxicity.

  1979cited by this paper
• Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine.

  1979cited by this paper
• Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil.

  1978cited by this paper
• Metabolic transformations of 5-azauracil and 5-azaorotic acid in mouse liver and Escherichia coli. Effect on the synthesis of pyrimidines.

  1972cited by this paper
• Studies on the coordinate activity and liability of orotidylate phosphoribosyltransferase and decarboxylase in human erythrocytes, and the effects of allopurinol administration.

  1971cited by this paper
• Orotidinuria Induced by Allopurinol

  1970cited by this paper
• Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate.

  1970cited by this paper
• Investigations with 5‐azaorotic acid, an inhibitor of the biosynthesis of pyrimidines de novo

  1965cited by this paper
• 5-azaorotic acid and related inhibitors of the synthesis de novo of pyrimidine nucleotides.

  1963cited by this paper
• Phosphorus compounds in animal tissues; a comparison of methods for the estimation of nucleic acids.

  1946cited by this paper

• Combination of potassium oxonate with anti-PD-1 for the treatment of colorectal cancer

  2025cites this paper
• Extraction and Identification of Polysaccharide from Lentinus edodes and Its Effect on Immunosuppression and Intestinal Barrier Injury Induced by Cyclophosphamide

  2024cites this paper
• Combination Chemotherapy With TS-1 and Cisplatin for Urinary Adenocarcinoma: A Retrospective Case Series.

  2024cites this paper
• Combination of S-1 and the oral ATR inhibitor ceralasertib is effective against pancreatic cancer cells

  2024cites this paper
• Efficacy and safety of SOXIRI versus mFOLFIRINOX in advanced pancreatic cancer

  2023cites this paper
• A randomized phase III study of docetaxel alone versus docetaxel plus S‐1 in patients with previously treated non‐small cell lung cancer: JMTO LC09‐01

  2023cites this paper
• Lineage of drug discovery research on fluorinated pyrimidines: chronicle of the achievements accomplished by Professor Setsuro Fujii

  2023cites this paper
• Postoperative Early Body Weight Loss Is a Risk Factor for Recurrence in Patients with pStage III Gastric Cancer

  2023cites this paper
• Evaluation of clinical validity of an S-1 dosage formula based on renal function using data of the SPIRITS and the G-SOX trials

  2022cites this paper
• Usefulness of an S-1 dosage formula: an exploratory analysis of randomized clinical trial (JCOG1001)

  2022cites this paper
• Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors

  2021cites this paper
• A Phase I Trial of Oxaliplatin, Irinotecan, and S‐1 Combination Therapy (OX‐IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403)

  2021cites this paper
• Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors

  2020cites this paper
• Prexasertib increases the sensitivity of pancreatic cancer cells to gemcitabine and S‑1

  2020cites this paper
• Pharmacokinetic and bioequivalence study of new S-1 capsule in Chinese cancer patients.

  2020cites this paper
• Current Status of Therapeutic Drug Monitoring of 5-Fluorouracil Prodrugs

  2020cites this paper
• A Study on the Effect and Mechanism of Xiaoaiping (XAP) Injection and S-1 Combination Therapy in Inhibiting the Invasion and Metastasis of Human GC Cells.

  2020cites this paper
• Safety of apatinib plus S-1 for advanced solid tumor as palliative treatment

  2020cites this paper
• Triplet chemotherapy with docetaxel, cisplatin and S-1 for unresectable advanced squamous cell carcinoma of the esophagus: phase I/II trial results

  2019cites this paper
• Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients

  2019cites this paper
• Effect of Lentinan on Peyer's patch structure and function in an immunosuppressed mouse model.

  2019cites this paper
• Clinical impact of renal impairment on the safety and efficacy of S-1 plus oxaliplatin in patients with advanced gastric cancer: a single institutional study.

  2019cites this paper
• Dihydropyrimidine dehydrogenase in the metabolism of the anticancer drugs

  2019cites this paper
• Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma

  2019cites this paper
• TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study

  2019cites this paper
• Concurrent chemoradiotherapy using cisplatin and S-1, followed by surgery for stage II/IIIA non-small cell lung cancer

  2019cites this paper
• Pharmacokinetic study of the oral fluorouracil antitumor agent S‐1 in patients with impaired renal function

  2019cites this paper
• Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients

  2019cites this paper
• NEPHROTOXICITY OF 5-FLUOROURACIL IN MALE MICE AND THE PROBABLE PROTECTIVE ROLE OF VITAMIN C: HISTOLOGICAL AND ULTRASTRUCTURAL STUDIES

  2019cites this paper
• A feasibility study of postoperative adjuvant chemotherapy with fluoropyrimidine S-1 in patients with stage II-IIIA non-small cell lung cancer.

  2018cites this paper
• 5‐Chloro‐2,4‐dihydroxypyridine, CDHP, prevents lung metastasis of basal‐like breast cancer cells by reducing nascent adhesion formation

  2018cites this paper
• Impact of relative dose intensity on bone marrow suppression induced by S-1: retrospective observational study

  2018cites this paper
• A retrospective study of concurrent radiotherapy plus S-1 for treating advanced non-small cell lung cancer

  2018cites this paper
• Complete remission of peritoneal dissemination of colon cancer by alternate-day S-1 and oxaliplatin plus bevacizumab treatment and maintenance chemotherapy comprising alternate-day S-1 plus bevacizumab: A case report.

  2018cites this paper
• Proposal and Practical Research for “Module Drug Discovery” Regarding Anticancer Drugs

  2018cites this paper
• A Phase II Study of S-1 in Elderly Patients with Unresectable Pancreatic Cancer

  2018cites this paper
• Pharmacokinetic Enhancers (Boosters)-Escort for Drugs against Degrading Enzymes and Beyond.

  2018cites this paper
• Combination TS‐1 plus EGFR‐tyrosine kinase inhibitors (TKIs) for the treatment of non‐small cell lung cancer after progression on first‐line or further EGFR‐TKIs: A phase II, single‐arm trial

  2018cites this paper
• 替吉奥治疗晚期非小细胞肺癌三线及以上患者的疗效分析

  2018cites this paper
• Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease

  2018cites this paper
• Correction to: S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)

  2018cites this paper
• Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer

  2017cites this paper
• Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer

  2017cites this paper
• Phase II study of S‐1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off

  2017cites this paper
• Drug delivery of oral anti-cancer fluoropyrimidine agents

  2017cites this paper
• Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer

  2017cites this paper
• Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003)

  2017cites this paper
• Alleviating effects of artificial tear instillation on S-1-induced ocular toxicity in dogs.

  2017cites this paper
• Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents

  2017cites this paper
• Meta-analysis Exploring the Effectiveness of S-1-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer.

  2017cites this paper
• Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analysis

  2016cites this paper
• A multicenter phase II study of concurrent chemoradiotherapy with cisplatin and oral S-1, followed by surgery for locally advanced non-small-cell lung cancer

  2016cites this paper
• Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models

  2016cites this paper
• Monitoring genotoxicity in patients receiving chemotherapy for cancer: application of the PIG-A assay.

  2016cites this paper
• S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)

  2016cites this paper
• S-l combined with cisplatin plus concurrent chemoradiotherapy versus cisplatin plus concurrent chemoradiotherapy for Chinese patients with advanced gastric cancer: a multi-centre randomized controlled trial

  2016cites this paper
• Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer

  2016cites this paper
• Therapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer

  2016cites this paper
• Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer

  2015cites this paper
• Emerging role of S-1 in gastric cancer

  2015cites this paper
• Postgastrectomy pharmacokinetic changes of S‐1 in patients with localized advanced gastric cancer

  2015cites this paper
• A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer

  2015cites this paper
• Clinical study of tegafur-gimeracil-oteracil potassium capsule (s-1) and oxaliplatin combination chemotherapy in advanced colorectal cancer.

  2015cites this paper
• Evaluation of Thymidylate Synthase Expression in Prostate Cancer

  2015cites this paper
• An Experimental Study to Assess Toxic Potential of Jayapala (Croton Tiglium) Beeja in Relation to Gastrointestinal Tract.

  2015cites this paper
• Pharmacokinetic changes of drugs in a rat model of liver cirrhosis induced by dimethylnitrosamine, alone and in combination with diabetes mellitus induced by streptozotocin.

  2015cites this paper
• Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer A Systematic Review and Meta-Analysis

  2015cites this paper
• Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study

  2015cites this paper
• Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer A Systematic Review and Meta-Analysis

  2015cites this paper
• Prognostic Impact of the ABCC11/MRP8 Polymorphism in Adjuvant Oral Chemotherapy with S-1 for Non-Small Cell Lung Cancer

  2015cites this paper
• Usefulness of alternate-day administration of S-1 and leucovorin in a xenograft mouse model of colorectal cancer: a shorter drug-free interval leads to more efficient antitumor effects

  2015cites this paper
• The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.

  2015cites this paper
• Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS)

  2015cites this paper
• Adjuvant S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma.

  2015cites this paper
• Reduction in gastrointestinal toxicity by gastric secretion inhibitors during S-1 monotherapy for patients with gastric cancer.

  2014cites this paper
• Thymidine phosphorylase mRNA expression may be a predictor of response to post-operative adjuvant chemotherapy with S-1 in patients with stage III colorectal cancer

  2014cites this paper
• Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer

  2014cites this paper
• DNA synthesis inhibitors for the treatment of gastrointestinal cancer

  2014cites this paper
• Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.

  2014cites this paper
• S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil.

  2014cites this paper
• Efficacy of S-1 in colorectal cancer

  2014cites this paper
• A systemic analysis of S-1 regimens for treatment of patients with colon cancer.

  2014cites this paper
• Radiotherapy concurrent with S-1 and radiotherapy alone for T2N0 glottic carcinoma: a retrospective comparative study.

  2014cites this paper
• Randomised phase II trial of photodynamic therapy plus oral fluoropyrimidine, S-1, versus photodynamic therapy alone for unresectable hilar cholangiocarcinoma.

  2014cites this paper
• S-1 in the treatment of pancreatic cancer.

  2014cites this paper
• Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancer.

  2014cites this paper
• Final results of a phase II study of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma.

  2014cites this paper
• S-1-Based versus Capecitabine-Based Preoperative Chemoradiotherapy in the Treatment of Locally Advanced Rectal Cancer: A Matched-Pair Analysis

  2014cites this paper
• Standing the test of time: targeting thymidylate biosynthesis in cancer therapy

  2014cites this paper
• S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil.

  2014cites this paper
• Development and validation of a HPLC-MS/MS method with electrospray ionization for quantitation of potassium oxonate in human plasma: Application to a pharmacokinetic study

  2013cites this paper
• Abrogation of 5-flourouracil induced renal toxicity by bee propolis via targeting oxidative stress and inflammation in Wistar rats

  2013cites this paper
• Bioequivalence Studies of A Generic Formulation (SW651K) to the BrandDrug S-1 in Tumor-Bearing Rat Models

  2013cites this paper
• A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer

  2013cites this paper
• A Retrospective Study of the Novel Combination of Paclitaxel and S1 for Pretreated Advanced Non-Small Cell Lung Cancer

  2013cites this paper
• [Development of siRNA delivery strategy by active control of tumor microenvironment].

  2013cites this paper
• Oral Anticancer Drugs: Mechanisms of Low Bioavailability and Strategies for Improvement

  2013cites this paper
• A pilot study for preoperative concurrent chemoradiotherapy with S-1 and cisplatin for locally advanced gastric cancer.

  2013cites this paper
• Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency.

  2013cites this paper
• Clinical development of S-1 for non-small cell lung cancer: a Japanese perspective

  2013cites this paper